Oxford, UK – 21 December 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, and Sigma-Aldrich, a leading $1.7 billion life science and high technology company, today announced that they have signed a joint licence agreement for the LentiVector technology with GlaxoSmithKline (GSK), which provides GSK with access to the technology for research activities. Sigma-Aldrich is Oxford BioMedica’s strategic partner and exclusive licensee in the commercialisation of the LentiVector technology for research use. Financial details were not disclosed.
